menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

CAMBRIDGE, Mass. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc . (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced one oral presentation and four poster
Read More

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conferences in
Read More

Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

Interim Award concluded all technology in dispute was exclusively licensed to Intellia   Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update

NTLA-2001: Intends to submit an investigational new drug application in mid-2020 for lead in vivo program for the treatment of transthyretin amyloidosis On track to nominate first engineered cell therapy development candidate for the treatment of acute myeloid leukemia by end of 2019 Ends quarter
Read More

Intellia Therapeutics to Present at August Healthcare Investor Conference

CAMBRIDGE, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conference in
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update

CAMBRIDGE, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present second quarter 2019 results and operational highlights in
Read More

Intellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Actions Relating to Key CRISPR/Cas9 Genome Editing Technology

New patent interference proceeding initated by the United States Patent and Trademark Office (USPTO) will determine if the University of California, University of Vienna and Emmanuelle Charpentier (UC Group) were first to invent the use of CRISPR/Cas9 in eukaryotic cells, which could result in up
Read More

Intellia Therapeutics to Participate at June Healthcare Investor Conferences

CAMBRIDGE, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in
Read More

Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer

CAMBRIDGE, Mass. , May 28, 2019 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc. , (NASDAQ:NTLA) has named Laura Sepp-Lorenzino , Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and
Read More

Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update

Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosis Expects to nominate first engineered cell therapy development candidate for treatment of acute myeloid
Read More
RSS FEEDS
PRINT PAGE